Products for Research Use Only
RegisterLogin

Salirasib

CAT: 0804-HY-14754-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14754-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.
CAS Number
162520-00-5
Product Name Alternative
S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Ras
Type
Reference compound
Related Pathways
Autophagy; GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Salirasib.html
Purity
99.04
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C(O)C1=CC=CC=C1SC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C
Molecular Formula
C22H30O2S
Molecular Weight
358.54
Precautions
H302, H315, H319, H335
References & Citations
[1]Makovski V, et al. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. Int J Cancer. 2012 Mar 15;130 (6) :1420-9.|[2]Nevo Y, et al. Chapman J. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy. PLoS One. 2011 Mar 22;6 (3) :e18049.|[3]Charette N, et al. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer. 2010 Sep 22;9:256.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
T6163-01Salirasib
abx282347-01Salirasib (FTS)
A11572-25Salirasib 25mg
A11572-10Salirasib 10mg
A11572-5Salirasib 5mg

Popular Products